DrugPatentWatch Database Preview

Details for Patent: 9,018,368

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,018,368 protect, and when does it expire?

Patent 9,018,368 protects EXONDYS 51 and is included in one NDA.

This patent has twenty-seven patent family members in thirteen countries.

Summary for Patent: 9,018,368

Title:	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Abstract:	An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Inventor(s):	Wilton; Stephen Donald (Applecross, AU), Fletcher; Sue (Bayswater, AU), McClorey; Graham (Bayswater, AU)
Assignee:	The University of Western Australia (Crawley, AU)
Application Number:	14/316,603
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 9,018,368

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 9,018,368

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2004903474	Jun 28, 2004

International Family Members for US Patent 9,018,368

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	498685
Cyprus	1111447
Cyprus	1117475